Compare ERII & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | AQST |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 504.0M |
| IPO Year | 2008 | 2007 |
| Metric | ERII | AQST |
|---|---|---|
| Price | $8.11 | $4.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $17.07 | $9.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,987,000.00 | $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | $20.55 | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $8.14 | $2.68 |
| 52 Week High | $18.31 | $7.55 |
| Indicator | ERII | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 44.22 |
| Support Level | N/A | $4.00 |
| Resistance Level | $11.58 | $4.38 |
| Average True Range (ATR) | 0.42 | 0.20 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 1.61 | 6.07 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.